A multidisciplinary panel of 60 specialists has released the 2025 edition of the Chinese consensus on the diagnosis and treatment of prolactinomas, published in the Chinese Neurosurgical Journal on June 8, 2026. This evidence-based framework standardizes care across endocrinology, neurosurgery, and radiology to improve early detection and patient outcomes for the most common hormone-secreting pituitary tumor.
Standardizing Diagnostic Pathways
Early recognition remains the primary factor in preventing invasive tumor growth. According to the consensus, clinicians must prioritize serum prolactin testing for patients presenting with symptoms such as menstrual disorders, infertility, galactorrhea, or sexual dysfunction. However, the document warns against immediate diagnosis based solely on high prolactin levels. It requires healthcare professionals to systematically exclude other physiological, pharmacological, or pathological causes of hyperprolactinemia first.
The guidance also addresses technical challenges that often complicate diagnosis. Specialists are advised to account for the “Hook effect”—an analytical interference that can lead to falsely low results in patients with very high prolactin levels—and to screen for macroprolactinemia. For patients with complex or suspected hereditary presentations, the panel recommends formal genetic testing.
Prolactinomas account for nearly 50% of all hormone-secreting pituitary adenomas, but delayed diagnosis in children and adolescents may lead to larger, more invasive tumors.
Advancing Imaging and Surgical Protocols
Pituitary magnetic resonance imaging (MRI) is confirmed as the preferred diagnostic tool for diagnosing prolactinomas. The consensus suggests that dynamic contrast-enhanced MRI may increase sensitivity, particularly for identifying smaller microadenomas that standard imaging might miss. Beyond tumor detection, the guidelines provide a roadmap for vascular assessment; surgeons are urged to identify patients who require pre-operative vascular imaging to screen for associated intracranial aneurysms.
Prof. Sheyu Li of Sichuan University notes that this guidance moves the field toward individualized management. By moving away from “one-size-fits-all” approaches, the consensus provides specific strategies for high-risk groups, including pregnant women, male patients, and those whose tumors show resistance to standard medical therapies.
Pro Tip: When managing refractory cases, the consensus emphasizes a patient-centered, multidisciplinary model. If you are a clinician, consider integrating neurosurgery, endocrinology, and radiation oncology early in the treatment planning phase to ensure consistent, evidence-based outcomes.
Future Implications for Clinical Practice
The transition toward a standardized, multidisciplinary model is expected to reduce long-term complications and better preserve endocrine function. By aligning Chinese clinical practice with internationally recognized GRADE approach frameworks, the consensus aims to foster greater collaboration between hospitals. Professor Huijuan Zhu of the Chinese Academy of Medical Sciences characterizes the document as a “highly reliable reference” that bridges the gap between current scientific research and bedside care.
Long-term, the adoption of these guidelines is designed to improve the quality of life for patients globally by refining how drug resistance and pregnancy-associated prolactinomas are handled. The consensus serves as a foundation for future research, encouraging clinicians to pool data on rare or difficult-to-treat cases.
Frequently Asked Questions
What is the preferred imaging tool for prolactinomas?
Pituitary MRI remains the preferred diagnostic tool. The consensus suggests that dynamic contrast-enhanced MRI may be useful for detecting smaller tumors.
Why is early recognition important for prolactinoma patients?
Early detection prevents the development of larger, more invasive tumors, particularly in adolescents and children, and helps preserve fertility and endocrine function.
How does the new consensus address complex cases?
The guidance provides specific protocols for managing the Hook effect, macroprolactinemia, hereditary syndromes, and patients who are resistant to standard medical treatments.
Have you or your practice implemented multidisciplinary protocols for pituitary disorders? Share your experiences in the comments below or subscribe to our newsletter for more updates on clinical guidelines and medical research.
Related reading
